New technologies for drugs and biomaterials stabilization

fitalent, Royal Vellon fund managed by Clave Mayor, Geiser Pharma and Galenicumhan entered the capital of the biotechnology company AzureBÍO. The investment will be carried out through a capital increase of 800,000 euros.

AzureBio, founded in 2007, specializes in the application of new technologies stabilizing drugs and biomaterials to solve problems or cover needs in the scope of human health and is currently working on two projects. In addition, AzureBio offers “formulation services” to third parties for asset management principles and “Products stabilization” of reagents used in diagnosis and treatment of samples with biological activity

Its use is particularly indicated in disadvantaged countries where resources are limited. Currently, child vaccines are an important global market estimated at several billion euros (between 1,000 and 5,000 million euros for vaccine type). All with an urgent need for improvement for easier management and avoid potential infections associated with the reuse of hypodermic needles.